Company Quick10K Filing
Quick10K
Clorox
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$146.96 127 $18,720
10-Q 2019-03-31 Quarter: 2019-03-31
10-Q 2018-12-31 Quarter: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-K 2018-06-30 Annual: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-Q 2017-12-31 Quarter: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-K 2017-06-30 Annual: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-Q 2016-12-31 Quarter: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-K 2016-06-30 Annual: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-Q 2015-12-31 Quarter: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-K 2015-06-30 Annual: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-Q 2014-12-31 Quarter: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-K 2014-06-30 Annual: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-Q 2013-12-31 Quarter: 2013-12-31
8-K 2019-08-01 Earnings, Regulation FD, Exhibits
8-K 2019-05-01 Earnings, Regulation FD, Exhibits
8-K 2019-02-04 Earnings, Regulation FD, Exhibits
8-K 2018-12-04 Officers, Exhibits
8-K 2018-11-14 Shareholder Vote
8-K 2018-10-31 Earnings, Regulation FD, Exhibits
8-K 2018-08-02 Earnings, Regulation FD, Exhibits
8-K 2018-07-23 Officers, Exhibits
8-K 2018-05-23 Other Events, Exhibits
8-K 2018-05-07 Other Events, Exhibits
8-K 2018-04-02 M&A
8-K 2018-03-28 Officers
8-K 2018-03-12 Other Events, Exhibits
8-K 2018-01-17 Officers, Exhibits
AMTD TD Ameritrade Holding 29,550
ICUI ICU Medical 4,750
RUSHA Rush Enterprises 1,510
YMAB Y-mAbs Therapeutics 768
CEVA CEVA 532
HVT Haverty Furniture Companies 380
HRZN Horizon Technology Finance 158
IDSY ID Systems 100
WEBK Wellesley Bancorp 88
RTTR Ritter 8
CLX 2019-03-31
Part I - Financial Information
Item 1. Financial Statements
Note 1. Summary of Significant Accounting Policies
Note 3. Business Acquired
Note 4. Inventories, Net
Note 5. Financial Instruments and Fair Value Measurements
Note 6. Income Taxes
Note 7. Net Earnings per Share (Eps)
Note 8. Comprehensive Income
Note 9. Stockholders' Equity
Note 10. Employee Benefit Plans
Note 11. Other Contingencies and Guarantees
Note 12. Segment Results
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1.A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 6. Exhibits
EX-31.1 clxq3fy19exhibit311.htm
EX-31.2 clxq3fy19exhibit312.htm
EX-32 clxq3fy19exhibit32.htm

Clorox Earnings 2019-03-31

CLX 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Document
00.6667false--06-30Q320192019-03-310000021076 falseLarge Accelerated FilerCLOROX CO /DE/false50000000280000001400000012000000206100000021250000000.962.640.962.881.001.007500000007500000001587414611587414611279827671278882260.25000001.001.0050000005000000000000003075869430853235 0000021076 2018-07-01 2019-03-31 0000021076 2019-04-17 0000021076 2018-01-01 2018-03-31 0000021076 2019-01-01 2019-03-31 0000021076 2017-07-01 2018-03-31 0000021076 2019-03-31 0000021076 2018-06-30 0000021076 us-gaap:AccountingStandardsUpdate201618Member 2018-03-31 0000021076 us-gaap:AccountingStandardsUpdate201618Member 2017-06-30 0000021076 us-gaap:AccountingStandardsUpdate201618Member 2019-03-31 0000021076 us-gaap:AccountingStandardsUpdate201618Member 2018-06-30 0000021076 2017-06-30 0000021076 2018-03-31 0000021076 2017-10-01 2017-12-31 0000021076 clx:VenezuelanSubsidiaryMember 2018-01-01 2018-03-31 0000021076 clx:VenezuelanSubsidiaryMember 2018-07-01 2019-03-31 0000021076 clx:VenezuelanSubsidiaryMember 2011-07-01 2014-09-30 0000021076 clx:VenezuelanSubsidiaryMember 2017-07-01 2018-03-31 0000021076 clx:VenezuelanSubsidiaryMember 2019-01-01 2019-03-31 0000021076 clx:NutranextMember 2019-03-31 0000021076 clx:NutranextMember us-gaap:CustomerRelationshipsMember 2019-03-31 0000021076 clx:NutranextMember us-gaap:TrademarksMember 2019-03-31 0000021076 clx:NutranextMember 2018-04-02 0000021076 clx:NutranextMember 2018-04-02 2018-04-02 0000021076 clx:NutranextMember clx:LifestyleMember 2019-03-31 0000021076 clx:NutranextMember clx:HouseholdMember 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2017-07-01 2018-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2018-01-01 2018-03-31 0000021076 us-gaap:CommodityContractMember 2017-07-01 2018-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:CommodityContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2017-07-01 2018-03-31 0000021076 us-gaap:CommodityContractMember 2018-01-01 2018-03-31 0000021076 us-gaap:CommodityContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2018-01-01 2018-03-31 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2019-03-31 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2018-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2018-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2019-03-31 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2018-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2018-06-30 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2019-03-31 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2019-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0000021076 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0000021076 clx:SoybeanOilFuturesMember 2019-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2018-06-30 0000021076 clx:JetFuelSwapsMember 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2019-03-31 0000021076 clx:SoybeanOilFuturesMember 2018-06-30 0000021076 clx:JetFuelSwapsMember 2018-06-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2019-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2018-07-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2018-06-30 0000021076 2017-07-01 2018-06-30 0000021076 us-gaap:ScenarioForecastMember 2018-07-01 2019-06-30 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2017-07-01 2018-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2018-07-01 2019-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2018-01-01 2018-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2017-07-01 2018-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-07-01 2018-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-07-01 2018-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-07-01 2018-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000021076 clx:EvergreenProgramMember 2018-01-01 2018-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2018-07-01 2019-03-31 0000021076 clx:EvergreenProgramMember 2017-07-01 2018-03-31 0000021076 clx:A750MillionOpenMarketPurchaseProgramMember 2018-01-01 2018-03-31 0000021076 clx:EvergreenProgramMember 2018-07-01 2019-03-31 0000021076 clx:A750MillionOpenMarketPurchaseProgramMember 2017-07-01 2018-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-01-01 2019-03-31 0000021076 clx:EvergreenProgramMember 2019-01-01 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000021076 us-gaap:TreasuryStockMember 2017-12-31 0000021076 us-gaap:RetainedEarningsMember 2018-07-01 2019-03-31 0000021076 us-gaap:CommonStockMember 2018-06-30 0000021076 us-gaap:CommonStockMember 2018-12-31 0000021076 us-gaap:TreasuryStockMember 2018-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2018-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000021076 us-gaap:CommonStockMember 2017-06-30 0000021076 us-gaap:TreasuryStockMember 2018-12-31 0000021076 us-gaap:CommonStockMember 2017-12-31 0000021076 us-gaap:CommonStockMember 2018-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000021076 us-gaap:TreasuryStockMember 2017-07-01 2018-03-31 0000021076 us-gaap:CommonStockMember 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2018-07-01 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000021076 2017-12-31 0000021076 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-03-31 0000021076 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000021076 us-gaap:RetainedEarningsMember 2017-12-31 0000021076 us-gaap:RetainedEarningsMember 2017-07-01 2018-03-31 0000021076 us-gaap:RetainedEarningsMember 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000021076 us-gaap:RetainedEarningsMember 2018-07-01 0000021076 2018-07-01 0000021076 us-gaap:RetainedEarningsMember 2018-06-30 0000021076 us-gaap:RetainedEarningsMember 2018-03-31 0000021076 us-gaap:TreasuryStockMember 2017-06-30 0000021076 us-gaap:TreasuryStockMember 2018-03-31 0000021076 us-gaap:TreasuryStockMember 2019-03-31 0000021076 2018-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000021076 us-gaap:RetainedEarningsMember 2017-06-30 0000021076 us-gaap:RetainedEarningsMember 2018-12-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-07-01 2018-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-07-01 2019-03-31 0000021076 clx:RetirementIncomeMember country:US 2019-01-01 2019-03-31 0000021076 clx:RetirementIncomeMember country:US 2018-01-01 2018-03-31 0000021076 clx:RetirementIncomeMember country:US 2017-07-01 2018-03-31 0000021076 clx:RetirementIncomeMember country:US 2018-07-01 2019-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2019-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2018-07-01 2019-03-31 0000021076 clx:DickinsonCountyMichiganMatterMember 2018-07-01 2019-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2017-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2019-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2016-11-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2018-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2018-06-30 0000021076 clx:WalmartStoresIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:HomeCareMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:DietarySupplementsMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:ProfessionalProductsMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:ProfessionalProductsMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:HomeCareMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CharcoalMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:LaundryMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:ProfessionalProductsMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:DietarySupplementsMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CharcoalMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CharcoalMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CharcoalMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:DietarySupplementsMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:ProfessionalProductsMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:LaundryMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:LaundryMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:HomeCareMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:DietarySupplementsMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2017-07-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:LaundryMember 2018-01-01 2018-03-31 0000021076 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember clx:CleaningMember clx:HomeCareMember 2017-07-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2018-07-01 2019-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2017-07-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2017-07-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2017-07-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2017-07-01 2018-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2017-07-01 2018-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2018-01-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2019-01-01 2019-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2018-01-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2018-01-01 2018-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2018-01-01 2018-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-03-31 iso4217:USD iso4217:USD xbrli:shares clx:reportable_segment clx:repurchase_program xbrli:pure xbrli:shares clx:instrument



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
     
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the quarterly period ended March 31, 2019.
 
 
 
 
 
OR
 
 
 
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number: 1-07151
_________________________
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter) 
Delaware
31-0595760
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
 
 
1221 Broadway
 
Oakland, California
94612-1888
(Address of principal executive offices)
(Zip code)
(510) 271-7000
(Registrant's telephone number, including area code)
 
(Former name, former address and former fiscal year, if changed since last report)
_________________________
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer þ
Accelerated filer ¨
Non-accelerated filer ¨
Smaller Reporting Company ¨
Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
 
As of April 17, 2019, there were 127,367,814 shares outstanding of the registrant’s common stock ($1.00 par value).
 




PART I – FINANCIAL INFORMATION

Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except share and per share data)
 
 
Three Months Ended
 
Nine Months Ended
 
 
3/31/2019
 
3/31/2018
 
3/31/2019
 
3/31/2018
Net sales
 
$
1,551

 
$
1,517

 
$
4,587

 
$
4,433

Cost of products sold
 
 
878

 
 
868

 
 
2,593

 
 
2,502

Gross profit
 
 
673

 
 
649

 
 
1,994

 
 
1,931

Selling and administrative expenses
 
 
216

 
 
208

 
 
639

 
 
609

Advertising costs
 
 
161

 
 
150

 
 
445

 
 
424

Research and development costs
 
 
34

 
 
32

 
 
98

 
 
95

Interest expense
 
 
24

 
 
20

 
 
72

 
 
61

Other (income) expense, net
 
 
(2
)
 
 
(3
)
 
 
8

 
 
(6
)
Earnings from continuing operations before income taxes
 
 
240

 
 
242

 
 
732

 
 
748

Income taxes on continuing operations
 
 
53

 
 
61

 
 
153

 
 
142

Earnings from continuing operations
 
 
187

 
 
181

 
 
579

 
 
606

Earnings (losses) from discontinued operations, net of tax
 
 

 
 

 
 

 
 

Net earnings
 
$
187

 
$
181

 
$
579

 
$
606

Net earnings (losses) per share
 
 
 
 
 
 
 
 
 
 
 
 
Basic
 
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
1.46

 
$
1.39

 
$
4.53

 
$
4.69

Discontinued operations
 
 

 
 

 
 

 
 

Basic net earnings per share
 
$
1.46

 
$
1.39

 
$
4.53

 
$
4.69

Diluted
 
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
 
$
1.44

 
$
1.37

 
$
4.45

 
$
4.60

Discontinued operations
 
 

 
 

 
 

 
 

Diluted net earnings per share
 
$
1.44

 
$
1.37

 
$
4.45

 
$
4.60

Weighted average shares outstanding (in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
Basic
 
 
128,404

 
 
129,694

 
 
128,092

 
 
129,357

Diluted
 
 
130,266

 
 
131,900

 
 
130,218

 
 
131,703

 
 
 
 
 
 
 
 
 
 
 
 
 
Comprehensive income
 
$
200

 
$
180

 
$
562

 
$
624












See Notes to Condensed Consolidated Financial Statements (Unaudited)

2



The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except share and per share data)
 
3/31/2019
 
6/30/2018
 
(Unaudited)
 
 
 
ASSETS
 
 
 
 
 
Current assets
 
 
 
 
 
Cash and cash equivalents
$
178

 
$
131

Receivables, net
 
587

 
 
600

Inventories, net
 
556

 
 
506

Prepaid expenses and other current assets
 
72

 
 
74

Total current assets
 
1,393

 
 
1,311

Property, plant and equipment, net of accumulated depreciation and amortization
        of $2,125 and $2,061, respectively
 
1,000

 
 
996

Goodwill
 
1,589

 
 
1,602

Trademarks, net
 
791

 
 
795

Other intangible assets, net
 
124

 
 
134

Other assets
 
265

 
 
222

Total assets
$
5,162

 
$
5,060

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
 
 
Current liabilities
 
 
 
 
 
Notes and loans payable
$
321

 
$
199

Accounts payable and accrued liabilities
 
940

 
 
1,001

Total current liabilities
 
1,261

 
 
1,200

Long-term debt
 
2,286

 
 
2,284

Other liabilities
 
774

 
 
778

Deferred income taxes
 
60

 
 
72

Total liabilities
 
4,381

 
 
4,334

Commitments and contingencies
 


 
 


Stockholders’ equity
 
 
 
 
 
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none
issued or outstanding
 

 
 

Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares
issued as of March 31, 2019 and June 30, 2018; and 127,888,226 and 127,982,767 shares outstanding as of March 31, 2019 and June 30, 2018, respectively
 
159

 
 
159

Additional paid-in capital
 
1,033

 
 
975

Retained earnings
 
3,004

 
 
2,797

Treasury shares, at cost: 30,853,235 and 30,758,694 shares as of March 31, 2019
        and June 30, 2018, respectively
 
(2,851
)
 
 
(2,658
)
Accumulated other comprehensive net (loss) income
 
(564
)
 
 
(547
)
Stockholders’ equity
 
781

 
 
726

Total liabilities and stockholders’ equity
$
5,162

 
$
5,060




See Notes to Condensed Consolidated Financial Statements (Unaudited)

3



The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
 
Nine Months Ended
 
3/31/2019
 
3/31/2018
 
 
 
 
(As Adjusted*)
Operating activities:
 
 
 
 
 
Net earnings
$
579

 
$
606

Deduct: Losses from discontinued operations, net of tax
 

 
 

Earnings from continuing operations
 
579

 
 
606

Adjustments to reconcile earnings from continuing operations to net cash
provided by continuing operations:
 
 
 
 
 
Depreciation and amortization
 
133

 
 
121

Stock-based compensation
 
34

 
 
37

Deferred income taxes
 
(7
)
 
 
(43
)
Other
 
(29
)
 
 
24

Changes in:
 
 
 
 
 
Receivables, net
 
11

 
 
(29
)
Inventories, net
 
(51
)
 
 
(58
)
Prepaid expenses and other current assets
 
(10
)
 
 
(2
)
Accounts payable and accrued liabilities
 
(55
)
 
 
(64
)
Income taxes payable/receivable, net
 
(2
)
 
 
(16
)
Net cash provided by continuing operations
 
603

 
 
576

Net cash provided by discontinued operations
 

 
 

Net cash provided by operations
 
603

 
 
576

Investing activities:
 
 
 
 
 
Capital expenditures
 
(135
)
 
 
(126
)
Other
 
9

 
 
14

Net cash used for investing activities
 
(126
)
 
 
(112
)
Financing activities:
 
 
 
 
 
Notes and loans payable, net
 
117

 
 
657

Long-term debt borrowings, net of issuance costs
 

 
 
396

Long-term debt repayments
 

 
 
(400
)
Treasury stock purchased
 
(315
)
 
 
(70
)
Cash dividends paid
 
(368
)
 
 
(326
)
Issuance of common stock for employee stock plans and other
 
137

 
 
35

Net cash (used for) provided by financing activities
 
(429
)
 
 
292

Effect of exchange rate changes on cash, cash equivalents, and restricted cash
 
(2
)
 
 
2

Net increase in cash, cash equivalents, and restricted cash
 
46

 
 
758

Cash, cash equivalents, and restricted cash:
 
 
 
 
 
Beginning of period
 
134

 
 
419

End of period
$
180

 
$
1,177


*Adjusted to reflect the retrospective adoption of Accounting Standards Update (ASU) No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” effective July 1, 2018. As of March 31, 2019 and 2018 and June 30, 2018 and 2017, the Company had $2, $3, $3 and $2 of restricted cash, respectively, and the restricted cash was included in Prepaid expenses and other current assets and Other assets in the condensed consolidated balance sheets.

See Notes to Condensed Consolidated Financial Statements (Unaudited)

4



The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except share and per share data)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2019 and 2018, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain prior year reclassifications were made in the condensed consolidated statements of cash flows to conform to the current year presentation. The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2018, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Revenue Recognition

Revenue is recognized when performance obligations under the terms of the contracts with customers are satisfied. The Company's performance obligation generally consists of the promise to sell finished products to wholesalers, distributors, retailers or consumers. Control of finished products is transferred upon shipment to, or receipt at, customers' locations, as determined by the specific terms of the contract. Once control is transferred to the customer, the Company has completed its performance obligation, and revenue is recognized. After completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.

The Company routinely commits to one-time or ongoing trade-promotion programs with customers and consumer coupon programs that require the Company to estimate and accrue the expected costs of such programs, which include shelf price reductions, end-of-aisle or in-store displays of the Company’s products and graphics and other trade-promotion activities conducted by the customer. The costs of such activities, defined as variable consideration under Topic 606 of the Accounting Standards Codification, "Revenue from Contracts with Customers," are netted against sales and recorded when the related sale takes place. The accruals for trade promotion programs and consumer coupon liabilities are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses forecasted appropriations, historical trend analysis, and customer and sales organization inputs in determining the accruals for promotional activities, and uses historical trend experience and coupon redemption estimates for the coupon accrual requirements.

The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging. Receivables are presented net of the allowance for doubtful accounts.

Foreign Currency Transactions and Translation

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, "Clorox Argentina"). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina are recognized in Other (income) expense, net in the condensed consolidated statement of earnings.



5

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In February 2018, the Financial Accounting Standards Board (FASB) issued ASU No. 2018-02, “Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which amends its guidance to allow a reclassification from Accumulated Other Comprehensive Income to Retained Earnings for the stranded income tax effects resulting from The Tax Cuts and Jobs Act of 2017 (the Tax Act). If elected, this reclassification adjustment may be applied to either the period of adoption or retrospectively to the periods impacted by the Tax Act. The amendments are effective for the Company beginning in the first quarter of fiscal year 2020, with early adoption permitted. The Company expects to early adopt this guidance in, and apply it to, the fourth quarter of fiscal year 2019. The Company is evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.
In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities,” which amends the hedge accounting recognition and presentation requirements to better align an entity’s risk management activities with its financial reporting. This standard also simplifies the application of hedge accounting in certain situations. The new guidance is effective for the Company beginning in the first quarter of fiscal year 2020, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The new guidance is effective for the Company beginning in the first quarter of fiscal year 2021, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize a right-of-use asset and a lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation will depend on the classification of a lease as either a finance or an operating lease. ASU 2016-02 also requires expanded disclosures about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-11, "Leases (Topic 842), Targeted Improvements," which provides an optional transition method in applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or, as permitted by ASU 2018-11, at the beginning of the period in which it is adopted. The Company will adopt the new standard on July 1, 2019, on a modified retrospective basis using the optional transition method, and, accordingly, will not restate comparative periods. The Company has initiated its plan for the adoption and implementation of this new accounting standard, including assessing its lease arrangements and implementing software to meet the reporting and disclosure requirements of this standard. Additionally, the Company is in the process of identifying changes to its business processes and controls to support the adoption and is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements. Refer to Note 12 of the Notes to Consolidated Financial Statements in Form 10-K for the fiscal year ended June 30, 2018 for the future minimum annual lease payments required under the Company’s existing non-cancelable operating and capital lease arrangements as of June 30, 2018.



6

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Adopted Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which replaces most of the existing U.S. GAAP revenue recognition guidance and is intended to improve and converge with international standards on the financial reporting requirements for revenue from contracts with customers. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 also requires additional disclosures about the nature, timing and uncertainty of revenue and cash flows arising from contracts with customers, including information about significant judgments and changes in judgments.

The Company adopted the new guidance on a modified retrospective basis effective July 1, 2018, and does not expect the guidance to have a material impact on the Company's annual consolidated financial statements. However, there will be an impact on the Company’s financial results in the interim periods due to the timing of recognition for certain trade promotion spending. Due to a change in the timing of recognition for certain trade promotion spending, the Company recorded an immaterial cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2019 opening balance of Retained earnings. Results for periods beginning on or after July 1, 2018 are recognized and presented in accordance with Topic 606, while prior period amounts have not been adjusted and continue to be reported in accordance with the prior accounting guidance under Topic 605, "Revenue Recognition." The Company has made changes to its accounting policies, business processes, systems and controls to align with the new revenue recognition guidance and disclosure requirements.

In March 2017, the FASB issued ASU No. 2017-07, “Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost,” which requires presenting the service cost component of net periodic benefit cost in the same income statement line items as other employee compensation costs arising from services rendered during the period. This standard also requires that other components of the net periodic benefit cost be presented separately from the line item(s) that includes service costs and outside of any subtotal of operating income, if one is presented, on a retrospective basis. The Company adopted this new guidance in the first quarter of fiscal year 2019 and the adoption did not have a material impact on the Company's consolidated financial statements. Following the adoption of this guidance, the Company records the non-service cost components of net periodic benefit cost in Other (income) expense, net.

In March 2018, the FASB issued ASU No. 2018-05, “Income Taxes (Topic 740)-Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118,” which amends its guidance to address the initial accounting for the income tax effects of the Tax Act, which was enacted on December 22, 2017 (enactment date). This guidance allowed reasonable estimates of income tax effects to be reported as provisional amounts during the measurement period, which is one year from the enactment date, when the necessary information is not available, prepared, or analyzed in sufficient detail to complete the accounting. The amendments also added specific disclosure requirements. The Company adopted this new guidance and initially recorded $81 of provisional benefits in the second quarter of fiscal year 2018. Refer to Note 6 for more information.




7


NOTE 2. DISCONTINUED OPERATIONS
On September 22, 2014, the Company's Venezuela affiliate, Corporación Clorox de Venezuela S.A. (Clorox Venezuela) announced that it was discontinuing its operations, effective immediately, and seeking to sell its assets. Since fiscal year 2012, Clorox Venezuela has been required to sell more than two thirds of its products at prices frozen by the Venezuelan government. During this same period, Clorox Venezuela experienced successive years of hyperinflation resulting in significant sustained increases in its input costs, including packaging, raw materials, transportation and wages. As a result, Clorox Venezuela had been selling its products at a loss, resulting in ongoing operating losses. Clorox Venezuela repeatedly met with government authorities in an effort to help them understand the rapidly declining state of the business, including the need for immediate, significant and ongoing price increases and other critical remedial actions to address these adverse impacts. Based on the Venezuelan government’s representations, Clorox Venezuela had expected significant price increases would be forthcoming much earlier; however, the price increases subsequently approved were insufficient and would have caused Clorox Venezuela to continue operating at a significant loss into the foreseeable future. As such, Clorox Venezuela was no longer financially viable and was forced to discontinue its operations.
On September 26, 2014, the Company reported that Venezuelan Vice President Jorge Arreaza announced, with endorsement by President Nicolás Maduro, that the Venezuelan government had occupied the Santa Lucía and Guacara production facilities of Clorox Venezuela. On November 6, 2014, the Company reported that the Venezuelan government had published a resolution granting a government-sponsored Special Administrative Board full authority to restart and operate the business of Clorox Venezuela, thereby reaffirming the government's expropriation of Clorox Venezuela’s assets. Further, President Nicolás Maduro announced the government's intention to facilitate the resumed production of bleach and other cleaning products at Clorox Venezuela plants. He also announced his approval of a financial credit to invest in raw materials and production at the plants. These actions by the Venezuelan government were taken without the consent or involvement of Clorox Venezuela, its parent Clorox Spain S.L. (Clorox Spain) or any of their affiliates. Clorox Venezuela, Clorox Spain and their affiliates reserved their rights under all applicable laws and treaties.
With this exit, the financial results of Clorox Venezuela are reflected as discontinued operations in the Company’s condensed consolidated financial statements for all periods presented. The results of Clorox Venezuela had historically been part of the International reportable segment.
There were no net sales for each of the three and nine months ended March 31, 2019 and 2018, and losses from discontinued operations, net of tax were insignificant for these same periods.


8


NOTE 3. BUSINESS ACQUIRED

On April 2, 2018, the Company acquired 100 percent of Nutranext, a health and wellness company based in Sunrise, Florida. Nutranext manufactures and markets leading dietary supplement brands in the retail and e-commerce channels as well as in its direct-to-consumer business. The purchase of the business reflects the Company's strategy to acquire leading brands in fast-growing categories with attractive gross margins and a focus on health and wellness.

The total consideration paid of $681, which included post-closing working capital and other adjustments, was initially funded through commercial paper borrowings and subsequently repaid using a combination of long-term debt financing and cash repatriated from foreign subsidiaries. The assets and liabilities of Nutranext were recorded at their respective estimated fair value as of the acquisition date using U.S. GAAP for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the Lifestyle and Household reportable segments of $310 and $102, respectively. The goodwill of $412 is primarily attributable to the synergies, including those with the digestive health business, expected to arise after the acquisition and reflects the value of further expanding the Company’s portfolio into the health and wellness arena. Of the total goodwill, $363 is expected to be deductible for tax purposes.

The following table summarizes the final purchase price allocation for the fair value of Nutranext's assets acquired and liabilities assumed and the related deferred income taxes as of March 31, 2019. The fair value of the assets acquired and liabilities assumed reflects the final insignificant measurement period adjustments related to goodwill, deferred income taxes and income taxes payable. The weighted-average estimated useful life of intangible assets subject to amortization is 15 years.
 
Nutranext
Goodwill ($310 in Lifestyle reportable segment and $102 in Household reportable segment)
$
412

Trademarks
143

Customer relationships
75

Property, plant and equipment
49

Working capital, net
22

Deferred income taxes
(20
)
Consideration paid
$
681


Effective April 2, 2018, Nutranext was consolidated into the Company's results of operations. Results for Nutranext's global business are reflected in the Lifestyle reportable segment.
Pro forma results reflecting the acquisition were not presented because the acquisition did not meet the threshold requirements for additional disclosure.

NOTE 4. INVENTORIES, NET
Inventories, net, consisted of the following as of:
 
3/31/2019
 
6/30/2018
Finished goods
$
445

 
$
395

Raw materials and packaging
136

 
129

Work in process
6

 
9

LIFO allowances
(31
)
 
(27
)
Total
$
556

 
$
506




9



NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of March 31, 2019, the notional amount of commodity derivatives was $29, of which $18 related to soybean oil futures used for the food business and $11 related to jet fuel swaps used for the charcoal business. As of June 30, 2018, the notional amount of commodity derivatives was $34, of which $24 related to soybean oil futures and $10 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $50 as of both March 31, 2019 and June 30, 2018.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate forward contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward contracts generally have durations of less than 12 months. The interest rate contracts are measured at fair value using information quoted by U.S. government bond dealers.

As of March 31, 2019 and June 30, 2018, the Company had no outstanding interest rate forward contracts.

10

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory, and interest rate forward contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive income and Net earnings were as follows:

 
Gains (losses) recognized in Other comprehensive income
 
Three Months Ended
 
Nine Months Ended
 
3/31/2019
 
3/31/2018
 
3/31/2019
 
3/31/2018
Commodity purchase derivative contracts
$
2

 
$

 
$
(4
)
 
$
3

Foreign exchange derivative contracts

 
1

 
1

 
1

Interest rate derivative contracts

 

 

 
2

Total
$
2

 
$
1

 
$
(3
)
 
$
6



 
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
 
Three Months Ended
 
Nine Months Ended
 
3/31/2019
 
3/31/2018
 
3/31/2019
 
3/31/2018
Commodity purchase derivative contracts
$
(1
)
 
$

 
$
(1
)
 
$

Foreign exchange derivative contracts
1

 

 
2

 
(1
)
Interest rate derivative contracts
(2
)
 
(1
)
 
(5
)
 
(5
)
Total
$
(2
)
 
$
(1
)
 
$
(4
)
 
$
(6
)


The gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings during the three and nine months ended March 31, 2019 and 2018, for commodity purchase and foreign exchange contracts were included in Cost of products sold, and for interest rate contracts were included in Interest expense.

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2019, which is expected to be reclassified into Net earnings within the next twelve months, is $(6). Gains and losses on derivative instruments representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in Net earnings. During the three and nine months ended March 31, 2019 and 2018, hedge ineffectiveness was not significant.


11

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instrument exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of March 31, 2019 and June 30, 2018, none contained such terms. As of March 31, 2019 and June 30, 2018, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings of the Company and its counterparties, as assigned by Standard & Poor’s and Moody’s, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2019 and June 30, 2018, the Company and each of its counterparties had been assigned investment grade credit ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of March 31, 2019 and June 30, 2018, the Company maintained cash margin balances related to exchange-traded futures contracts of $1 and $2, respectively, which are classified as Prepaid expenses and other current assets in the condensed consolidated balance sheets.

Trust Assets

The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of March 31, 2019 and June 30, 2018, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.

12

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The following table summarizes the fair value of the Company’s assets and liabilities for which disclosure of fair value is required:
 
 
 
 
 
3/31/2019
 
6/30/2018
 
Balance sheet
classification
 
Fair value
hierarchy
level
 
Carrying
Amount
 
Estimated
Fair
Value
 
Carrying
Amount
 
Estimated
Fair
Value
Assets
 
 
 
 
 
 
 
 
 
 
 
Investments, including money market funds
Cash and cash
equivalents
(a)
 
1
 
$
40

 
$
40

 
$
24

 
$
24

Time deposits
Cash and cash
equivalents
(a)
 
2
 
29

 
29

 
23

 
23

Commodity purchase swaps contracts
Prepaid expenses and other current assets
 
2
 
1

 
1

 
3

 
3

Foreign exchange forward contracts
Prepaid expenses and other current assets
 
2
 
1

 
1

 
2

 
2

Trust assets for nonqualified deferred compensation plans
Other assets
 
1
 
91

 
91

 
86

 
86

 
 
 
 
 
$
162

 
$
162

 
$
138

 
$
138

Liabilities
 
 
 
 
 
 
 
 
 
 
 
Notes and loans payable
Notes and loans payable (b)
 
2
 
$
321

 
$
321

 
$
199

 
$
199

Commodity purchase futures contracts
Accounts payable and accrued liabilities
 
1
 
1

 
1

 
1

 
1

Commodity purchase swaps contracts
Accounts payable and
accrued liabilities
 
2
 
1

 
1

 

 

Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt
(c)
 
2
 
2,286

 
2,353

 
2,284

 
2,269

 
 
 
 
 
$
2,609

 
$
2,676

 
$
2,484

 
$
2,469

____________________

(a)
Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(b)
Notes and loans payable is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
(c)
Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.







13



NOTE 6. INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings from continuing operations was 21.8% and 20.8% for the three and nine months ended March 31, 2019, respectively, and 25.5% and 19.0% for the three and nine months ended March 31, 2018, respectively. The decrease in the effective tax rate on continuing operations for the current three-month period was primarily due to the lower federal statutory tax rate for fiscal year 2019 as a result of enactment of the Tax Act, partially offset by the repeal of the domestic manufacturing deduction in fiscal year 2019. The lower effective tax rate on earnings from continuing operations for the prior nine-month period was primarily due to one-time tax benefits from the enactment of the Tax Act during the second quarter of fiscal year 2018 and the final year of domestic manufacturing deduction benefits in fiscal year 2018, partially offset by the lower federal statutory tax rate for fiscal year 2019.

The Tax Act was signed into law by the President of the United States on December 22, 2017. The Tax Act made significant changes to U.S. tax law, and included a reduction of U.S. corporation statutory income tax rates from 35% to 21%, effective January 1, 2018. Under the Tax Act, the Company was subject to an average federal statutory tax rate of 28.1% for its fiscal year ended June 30, 2018. The Company’s federal statutory tax rate was 21.0% beginning in July 2018 for the fiscal year ending June 30, 2019. The Tax Act also included, among other things, a one-time transition tax on accumulated foreign earnings and the adoption of a modified territorial approach to the taxation of future foreign earnings.

During the second quarter of fiscal year 2018, the Company made reasonable estimates of the impacts of the Tax Act and initially recorded total benefits of $81 as provisional, as defined in Staff Accounting Bulletin No. 118, as follows:
 
 
Adjustments
One-time net deferred tax liability reduction
 
$
60

One-time transition tax
 
(7
)
Net total one-time tax benefit
 
53

Beneficial year-to-date current taxable income impact
 
28

Total tax benefits
 
$
81



As of December 31, 2018, the Company completed its accounting for all of the enactment-date income tax effects of the Tax Act. Cumulative measurement adjustments through the second quarter of fiscal year 2019 were insignificant.

14



NOTE 7. NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
 
Three Months Ended
 
Nine Months Ended
 
3/31/2019
 
3/31/2018
 
3/31/2019
 
3/31/2018
Basic
128,404
 
129,694

 
128,092
 
129,357

Dilutive effect of stock options and other
1,862
 
2,206

 
2,126
 
2,346

Diluted
130,266
 
131,900

 
130,218
 
131,703

 
 
 
 
 
 
 
 
Antidilutive stock options and other
23
 
1,136

 
807
 
1,136




NOTE 8. COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
 
Three Months Ended
 
Nine Months Ended
 
3/31/2019
 
3/31/2018
 
3/31/2019
 
3/31/2018
Earnings from continuing operations
$
187

 
$
181

 
$
579

 
$
606

Earnings (losses) from discontinued operations, net of tax

 

 

 

Net earnings
187

 
181

 
579

 
606

Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustments
8

 
(4
)
 
(23
)
 
6

Net unrealized gains (losses) on derivatives
3

 
2

 
2

 
10

Pension and postretirement benefit adjustments
2

 
1

 
4

 
2

Total other comprehensive income (loss), net of tax
13

 
(1
)
 
(17
)
 
18

Comprehensive income
$
200

 
$
180

 
$
562

 
$
624





15


NOTE 9. STOCKHOLDERS EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:
 
Three Months Ended March 31
 
Common Stock
 
Additional Paid-in Capital
 
Retained Earnings
 
Treasury Stock
 
Accumulated
Other
Comprehensive
Net (Loss) Income
 
Total Stockholders Equity
 
Amount
 
Shares
(in thousands)
 
 
 
Amount
 
Shares
(in thousands)
 
 
Balance as of December 31, 2017
$
159

 
158,741

 
$
941

 
$
2,649

 
$
(2,465
)
 
(29,393
)
 
$
(524
)
 
$
760

Net earnings


 


 


 
181

 


 


 


 
181

Other comprehensive income (loss)


 


 


 


 


 


 
(1
)
 
(1
)
Dividends ($0.96 per share declared)


 


 


 
(125
)
 


 


 


 
(125
)
Stock-based compensation


 


 
14

 


 


 


 


 
14

Other employee stock plan activities


 


 
1

 
(1
)
 
8

 
141

 


 
8

Treasury stock purchased


 


 


 


 

 

 


 

Balance as of March 31, 2018
$
159

 
158,741

 
$
956

 
$
2,704

 
$
(2,457
)
 
(29,252
)
 
$
(525
)
 
$
837

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Balance as of December 31, 2018
$
159

 
158,741

 
$
1,014

 
$
2,940

 
$
(2,794
)
 
(30,651
)
 
$
(577
)
 
$
742

Net earnings


 


 


 
187

 


 


 


 
187

Other comprehensive income (loss)


 


 


 


 


 


 
13

 
13

Dividends ($0.96 per share declared)


 


 


 
(123
)
 


 


 


 
(123
)
Stock-based compensation


 


 
16

 


 


 


 


 
16

Other employee stock plan activities


 


 
3

 

 
16

 
264

 


 
19

Treasury stock purchased


 


 


 


 
(73
)
 
(466
)
 


 
(73
)
Balance as of March 31, 2019
$
159

 
158,741

 
$
1,033

 
$
3,004

 
$
(2,851
)
 
(30,853
)
 
$
(564
)
 
$
781

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended March 31
 
Common Stock
 
Additional Paid-in Capital
 
Retained Earnings
 
Treasury Stock
 
Accumulated
Other
Comprehensive
Net (Loss) Income
 
Total Stockholders Equity
 
Amount
 
Shares
(in thousands)
 
 
 
Amount
 
Shares
(in thousands)
 
 
Balance as of June 30, 2017
$
159

 
158,741

 
$
928

 
$
2,440

 
$
(2,442
)
 
(29,727
)
 
$
(543
)
 
$
542

Net earnings


 


 


 
606

 


 


 


 
606

Other comprehensive income (loss)


 


 


 


 


 


 
18

 
18

Dividends ($2.64 per share declared)


 


 


 
(343
)